A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
Phase 3
Terminated
- Conditions
- Diabetes Mellitus
- Registration Number
- NCT00287066
- Lead Sponsor
- Pfizer
- Brief Summary
To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes
- Detailed Description
The study was terminated on Oct. 28, 2007. The protocol was undergoing implementation and methodological issues with major revisions that qualified this trial as a new trial. Pfizer decided to cancel new trials because of the decision to withdraw Exubera due to lack of market performance and not for safety reasons.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- Diabetes mellitus Type 1
Exclusion Criteria
- Asthma, COPD
- Smoking
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method 18F-labeled glucose uptake in muscle
- Secondary Outcome Measures
Name Time Method Glucose turnover overnight Insulin pharmacokinetics
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸Pittsburgh, Pennsylvania, United States
Pfizer Investigational Site🇺🇸Pittsburgh, Pennsylvania, United States